[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:esophageal-carcinoma:programmed-cell-death-1-ligand-1":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Esophageal Carcinoma","Programmed Cell Death 1 Ligand 1",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07532902","A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:15:54.846520Z","2026-07-05T05:32:16.689344Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07431281","Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2",[20],"Phase 3","2026-08-26T02:16:04.914942Z","2026-05-05T02:43:29.651140Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT03526835","A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors",[27],"Phase 1\u002FPhase 2","2026-08-26T02:17:16.126291Z","2026-07-30T01:46:14.461456Z"]